21 April 2017
IntegraGen has announced its financial results for the year ending December 31, 2016. The financial statements were validated by the Company’s Board of Directors on April 20, 2017.
Link to press release
08 March 2017
IntegraGen SA and Laboratoire CERBA announced the signing of a licensing agreement allowing Laboratoire CERBA to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to prescribing clinicians in France, Benelux, Middle East and Africa. Laboratoire CERBA will develop this test to complement its existing portfolio (…) »
03 February 2017
IntegraGen today announced that it has successfully completed a capital increase with cancellation of preferential subscription rights, reserved for a category of investors in the amount of € 3.7 million.
Objectives of Fundraising
The funds received will permit IntegraGen to accelerate its development by (…) »
04 January 2017
IntegraGen will be in attendance at 35th Annual JP Morgan Healthcare Conference being held in San Francisco on January 9-12, 2017. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry which brings together global industry leaders, emerging fast-growth companies, innovative (…) »
14 October 2016
IntegraGen today announced its sales for the first half 2016. Sales for IntegraGen’s business totaled € 2.8 million as of June 30, 2016, and increase of 10% compared to the first half of 2015.
Sales of € 2.8 million, a 10% increase vs. H1 2015 Operational result +14% (…) »
10 October 2016
Data presented concludes that miR-31-3p expression is predictive of anti-EGFR therapy effect on objective response, depth of response, and early tumor shrinkage in patients with metastatic colorectal cancer enrolled in prospective, randomized FIRE-3 Trial.
Click here to view press release
04 October 2016
IntegraGen will be participating in the ODDO Forum being held at the Lyon Convention Center on 5 and 6 January 2017.
View the meeting program
03 October 2016
IntegraGen will present an update on the ICE Project (Interpretation of Clinical Exome) during the MEDICEN PARIS REGION meeting being held on Wednesday, October 5, 2016 at the headquarters of Bpifrance. This meeting will be attended by the organization’s members, partners and (…) »
04 September 2016
Results from a new analysis of the predictive miR 31-3p biomarker for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial will be featured as an oral presentation during a proffered session at the upcoming 2016 European Society of Medical Oncology (ESMO) Congress. Professor Pierre Laurent-Puig, (…) »
07 July 2016
IntegraGen has announced its sales for the first half 2016. The company reported strong growth for its clinical research and microbiology genomics businesses and stability in its genomic services business for research activities with a significant increase in orders across all genomic activities.
Link to press release